The research, published in Frontiers in Systems Biology, analyzed 700 patients hospitalized for postoperative intraoral bleeding after dental or oral surgery between January 2011 and December 2021. Rather than treating the cohort as a single uniform group, the team applied a statistical technique called latent class analysis to uncover recurring patterns of chronic disease hiding within the data. What emerged were five distinct multimorbidity classes, each with its own constellation of cardiovascular, metabolic, renal, and gastrointestinal conditions, and each with a tellingly different pattern of blood-thinning medication use.

The demographic profile of the cohort is striking on its own. The median age of hospitalized bleeding patients was 74 years, and nearly two-thirds, 65.7 percent, were men. Median hospital stay was just two days, suggesting that most episodes were stabilized quickly, but the underlying medical burden was enormous: 74.9 percent had documented cardiac disease, 48.0 percent had hypertension, 17.6 percent had diabetes, and roughly one in seven had undergone heart valve replacement or suffered from kidney disease. Critically, 83.0 percent were taking at least one antithrombotic medication at admission, meaning these patients were deliberately kept in a state of reduced clotting ability to protect them from heart attacks and strokes.

The study also captured a quiet revolution in prescribing practice. Over the eleven-year window, the balance shifted decisively from vitamin K antagonists, the older warfarin-style anticoagulants that require regular blood monitoring, toward direct oral anticoagulants, or DOACs, the newer agents that have swept into routine care for atrial fibrillation and venous thromboembolism. VKA monotherapy accounted for 36 hospitalized bleeding cases in 2011 and fell to just seven by 2021, while DOAC monotherapy rose from zero cases in 2011 to 25 in 2020. Combined antiplatelet and VKA therapy disappeared from the records entirely after 2016. The authors are careful to stress that these are counts among patients who bled, not medication-specific bleeding rates, because the number of patients taking each drug and undergoing dental procedures in the wider population was unknown.

The analytical heart of the paper lies in the latent class analysis. Of the 700 patients, 458 had at least two documented comorbidities and were subjected to a probabilistic modeling exercise using eleven binary indicators covering conditions from cardiac disease and hypertension to deep venous thrombosis, heart valve replacement, stroke, peripheral arterial disease, diabetes, renal disease, gastrointestinal disease, rheumatic disease, and hepatic disease. Latent class analysis works by assuming that observed patterns of diagnoses arise from a small number of unobserved patient subtypes, and it estimates both the characteristics of those subtypes and the probability that each individual belongs to one. The researchers compared models containing one to six classes using information criteria, entropy, a bootstrap likelihood ratio test, class sizes, and clinical interpretability.

The five-class solution emerged as the winner, though not without statistical tension. It had the lowest Akaike information criterion of any candidate, high entropy of 0.871 indicating precise classification, and a significant test favoring five classes over four. Yet the Bayesian information criterion actually preferred a two-class model, and the sample-size-adjusted variant preferred four. The six-class model failed outright, with a nonsignificant likelihood ratio test. The authors transparently report this disagreement, noting that the five-class solution should be considered an exploratory description requiring external replication rather than a definitive taxonomy.

The classes themselves are clinically evocative. Class 1, a small group of 26 patients, was defined by deep venous thrombosis together with cardiac disease and hypertension. Class 2, with 97 patients, was anchored by heart valve replacement and cardiac disease. Class 3, 55 patients, combined stroke, cardiac disease, and hypertension. Class 4, the largest at 151 patients, was characterized by hypertension and cardiac disease, while Class 5, 129 patients, displayed a broad multisystem cardiometabolic profile spanning cardiac disease, hypertension, diabetes, renal disease, and gastrointestinal disease. When the researchers cross-referenced medication use against these classes, a coherent pattern appeared: VKA use was concentrated in the thrombotic and valvular classes, where it reached 73.1 and 77.3 percent of patients respectively, while DOAC use peaked at 25.8 percent in the hypertensive-cardiac class. Antiplatelet monotherapy was more common in the cerebrovascular and multisystem classes.

That alignment between disease profile and drug choice is exactly what one would expect from rational prescribing, since the underlying indication drives anticoagulant selection, and it lends the latent classes face validity even though they were derived purely from diagnostic patterns. Stability testing through 100 bootstrap resamples yielded a mean adjusted Rand index of 0.607, a measure of classification agreement that the authors describe as moderate rather than high. Profile correlations were strong for the valvular and hypertensive-cardiac classes, above 0.96, but weaker for the small venous-thrombotic class and the cerebrovascular class, which is unsurprising given their smaller sizes and the inherent uncertainty of assigning patients probabilistically.

The clinical implications reach into one of the most persistent dilemmas in dental medicine: what to do with patients on blood thinners who need oral surgery. Stopping anticoagulation carries real dangers, including stroke and valve thrombosis, while continuing it raises the specter of uncontrolled bleeding. Existing evidence generally supports continuing antithrombotic therapy for many minor oral procedures with appropriate local hemostatic measures such as suturing, hemostatic dressings, and tranexamic acid mouthwashes, and the new study did not test any specific perioperative strategy. What it does provide is a richer description of the patients at the severe end of the bleeding spectrum, reinforcing that decisions must weigh the full comorbidity picture, the antithrombotic indication, the invasiveness of the procedure, and the available local measures together, ideally in interdisciplinary consultation.

The authors are careful about the limits of their design. Because the cohort contained only patients who had already bled badly enough to be hospitalized, with no comparator group of uneventful procedures, the study cannot identify risk factors, estimate medication-specific bleeding rates, or support causal claims. The admission INR of 1.28 reported for the cohort is a descriptive average across all patients, including those not on VKAs, and cannot be read as a measure of anticoagulation quality. Still, the scale of the dataset, its eleven-year span, the systematic dual-review chart abstraction, and the transparent handling of missing data give the findings real weight. Future work, the authors argue, should pair bleeding patients with matched controls, capture procedural denominators and medication exposure in the source population, and validate the multimorbidity classes in independent cohorts before they can be used to predict who is most likely to end up in a hospital bed after a trip to the dentist.

Subject of Research: Multimorbidity patterns and antithrombotic medication use in patients hospitalized for bleeding after dental surgery

Article Title: Latent multimorbidity classes and antithrombotic medication distributions among patients hospitalized for bleeding after dental surgery: a retrospective study

Article References: Wagner, J., Spille, J. H., Flor, J., Ouyang, Z., Conrad, J., Dörfer, C., Wiltfang, J., & Naujokat, H. (2026). Latent multimorbidity classes and antithrombotic medication distributions among patients hospitalized for bleeding after dental surgery: a retrospective study. Frontiers in Systems Biology, 6, Article 1917159. https://doi.org/10.3389/fsysb.2026.1917159

Image Credits: AI Generated

DOI: 10.3389/fsysb.2026.1917159

Keywords: latent class analysis, multimorbidity, dental surgery, postoperative bleeding, anticoagulants, DOACs, vitamin K antagonists, antiplatelet therapy, cardiovascular disease, retrospective study, oral surgery, hospitalization

The study, published in the journal Neurocritical Care, is a systematic review and Bayesian meta-analysis led by Paweł Łajczak of the Medical University of Silesia together with collaborators in Brazil and Poland. The team searched five major databases from their inception to January 2026 and, after rigorous screening, included seven comparative studies encompassing 731 patients with antiplatelet therapy-associated intracerebral hemorrhage, of whom 281 received desmopressin. Their conclusion is stark: there is currently no convincing evidence that desmopressin improves survival or functional recovery in these patients, and several statistical signals raise genuine concern for harm.

Desmopressin, also known as DDAVP, is a selective agonist of vasopressin V2 receptors. When administered, it triggers the release of von Willebrand factor and Factor VIII from endothelial stores, both of which are critical for platelets to adhere to damaged vessel walls and form a stable plug. Early exploratory work, including a 2014 study showing improved platelet activity after desmopressin administration in intracerebral hemorrhage, made the drug an attractive candidate for limiting hematoma expansion. The logic seemed airtight: if antiplatelet drugs paralyze platelets, and desmopressin re-arms them, bleeding should slow and outcomes should improve. The new analysis suggests the biology of spontaneous brain hemorrhage is far less cooperative than that simple model implies.

The stakes are considerable. Patients on dual antiplatelet therapy face a more than 40 percent higher risk of intracerebral hemorrhage compared with those taking aspirin alone, and studies show that patients who bleed while on antiplatelet agents have larger hemorrhage volumes at 24 hours and higher mortality than those who are not. Unlike anticoagulant reversal, the antiplatelet effect cannot be undone immediately, which is precisely why a fast-acting prohemostatic agent like desmopressin has been so appealing in the emergency setting.

Methodologically, the new review stands out for its statistical approach. Because only a small number of studies and patients exist in this literature, traditional frequentist meta-analysis risks overstated conclusions and unstable estimates. The authors instead employed a Bayesian random-effects model, run in the bayesmeta package in R, using three different priors: a vague prior for the overall effect size, informative log-normal priors derived from validated predictive distributions published by Turner and colleagues, and sensitivity analyses with weakly informative and vague half-normal priors for heterogeneity. Rather than declaring results simply significant or nonsignificant, the Bayesian framework yields posterior probability distributions, which quantify how likely an effect is to point in a given direction given the data and prior knowledge. The study was prospectively registered in PROSPERO and followed Cochrane Handbook and PRISMA guidelines.

The headline results were uniformly negative for benefit. Desmopressin showed no reduction in overall mortality, with an odds ratio of 1.23 and a 95 percent credible interval of 0.79 to 1.91, and no reduction in in-hospital mortality, with an odds ratio of 1.41 and a credible interval of 0.88 to 2.26. Good functional outcome, defined as a modified Rankin Scale score of 0 to 3 at last follow-up, was actually numerically worse in the desmopressin group, with an odds ratio of 0.66 and a credible interval of 0.34 to 1.31. Hematoma expansion over 33 percent, the mechanistic endpoint that desmopressin was supposed to prevent, showed a nonsignificant trend toward benefit with an odds ratio of 0.89, far short of credible statistical evidence. Adverse events, thromboembolic complications, and hyponatremia all trended toward higher rates with the drug.

The most unsettling findings emerged from the posterior distribution analyses. The model estimated a 74.88 percent probability that desmopressin increases thromboembolic events, roughly a 70 percent probability of increased adverse events overall, and an 82.28 percent likelihood that the drug is associated with lower odds of achieving a good functional outcome. The authors are careful to note that these probabilities should not be read as proof of harm, since the 95 percent credible intervals cross the null-effect line and no prespecified interpretive thresholds exist. But in the absence of any demonstrated baseline benefit, uncertain signals of potential harm carry considerable weight. The thrombotic concern has a plausible mechanism: patients who need antiplatelet therapy already carry high vascular morbidity, and flooding their circulation with von Willebrand factor and Factor VIII could tip the balance toward clot formation in coronary or cerebral vessels.

Only one of the seven included studies was randomized: the UK-based DASH trial, a phase 2, placebo-controlled feasibility study published in The Lancet Neurology in 2023. DASH found no significant differences in hematoma expansion, 21 percent with desmopressin versus 23 percent with placebo, nor in mortality or neurological outcomes. Intriguingly, its safety profile diverged sharply from the observational literature, with only one thromboembolic event in each arm, roughly 4 percent, whereas retrospective studies had reported much higher thrombotic rates. The authors suggest this discrepancy highlights how heavily confounded retrospective data can be, and they argue that fully powered phase 3 trials are essential before any definitive verdict on safety can be reached. The DASH trial itself was judged at low risk of bias, while the six nonrandomized studies showed concerns primarily around confounding, participant selection, and missing data, and all primary outcomes in the review were graded as low certainty under the GRADE framework.

Why does desmopressin fail to deliver in this population when it has shown promise in traumatic brain injury? The authors point to the pathophysiology of spontaneous intracerebral hemorrhage, where high blood pressure in small vessels physically disrupts platelet clot formation in ways that extra von Willebrand factor cannot fully rescue. Timing is another likely culprit: because hemorrhage strikes suddenly, many patients reach the intensive care unit too late for an ultra-early dose, and the optimal administration window may simply be too narrow to exploit. The review also underscores that desmopressin is only one variable among many. In one included cohort, the time from admission to first CT scan, platelet transfusion, and age were significant predictors of hematoma expansion, while in another multivariate model only increased age and the presence of intraventricular hemorrhage independently predicted poor short-term neurological outcome, with the intervention itself failing to reach significance.

The authors argue that the field must stop treating antiplatelet-associated hemorrhage as a homogeneous entity. Patients take different antiplatelet agents with different degrees of platelet inhibition and carry wildly different comorbidity profiles, and it remains unknown whether specific subpopulations might genuinely benefit from desmopressin. Future trials, they contend, should compare desmopressin directly against other prohemostatic agents and focus on identifying responsive subsets of patients tied to specific antiplatelet regimens. For now, the practical message for clinicians is sobering: routine desmopressin administration in spontaneous brain hemorrhage on antiplatelet therapy lacks demonstrated clinical benefit, and the possibility of thromboembolic harm demands that the drug be studied, not assumed, before it becomes standard of care.

Subject of Research: Effectiveness and safety of desmopressin in spontaneous intracerebral hemorrhage among patients on antiplatelet therapy

Article Title: Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis

Article References: Łajczak, P., de Oliveira, R. R., Łajczak, A., Paiva, W. S., & Bertani, R. (2026). Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis. Neurocritical Care. https://doi.org/10.1007/s12028-026-02672-3

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02672-3

Keywords: desmopressin, DDAVP, intracerebral hemorrhage, antiplatelet therapy, Bayesian meta-analysis, hematoma expansion, thromboembolic events, stroke, neurocritical care, von Willebrand factor, systematic review, DASH trial

Branch atheromatous disease, often abbreviated as BAD, is a distinct and clinically consequential subtype of acute ischemic stroke, accounting for roughly 9 to 20 percent of cases. First described by neurologist Louis Caplan in 1989, it involves atherosclerotic disease at the origin of penetrating arteries, the small deep vessels that branch off major cerebral arteries such as the middle cerebral artery and the basilar artery. This mechanism differs fundamentally from lacunar infarction caused by lipohyalinosis, and BAD is not well captured by the conventional TOAST classification system that has long organized ischemic stroke subtypes. With advances in magnetic resonance imaging, BAD is increasingly recognized as a single subcortical infarction extending along a perforator territory without severe stenosis of the parent artery.

What makes BAD so clinically troubling is its tendency toward early neurological deterioration, a phenomenon in which patients who initially present with mild deficits suddenly worsen, sometimes dramatically, within hours or days of onset. More than 30 percent of patients with BAD remain disabled at follow-up, a striking figure given that many arrive at the hospital with only minor symptoms. Paradoxically, the annual risk of recurrent stroke in BAD is relatively low, at less than 3.8 percent. This high disability, low recurrence profile suggests that the most meaningful treatment goal in this population is preventing early deterioration and improving functional outcome, rather than preventing recurrent ischemic events. Yet the mechanisms driving deterioration, including perforator hypoperfusion, local thrombosis, and inflammation, remain incompletely understood, and no guideline-endorsed therapy specifically addresses this subtype. Intravenous alteplase has not consistently prevented deterioration, and most patients lack a target suitable for mechanical thrombectomy.

Into this therapeutic vacuum stepped tirofiban, a reversible antagonist of the glycoprotein IIb/IIIa receptor on platelets. By blocking this receptor, tirofiban rapidly and potently inhibits platelet aggregation, the cellular process at the heart of clot formation. Prior randomized trials had suggested that tirofiban could safely improve outcomes in select acute ischemic stroke populations, including patients with disabling non-cardioembolic stroke and those receiving it as an adjunct after intravenous thrombolysis or endovascular treatment. On the strength of this indirect evidence, clinicians increasingly administered tirofiban empirically to patients with BAD-related stroke, despite the absence of randomized data in that specific population. The BRANT trial was designed to test whether this common practice was actually justified.

The trial enrolled adults aged 18 to 75 years who presented within 48 hours of stroke onset and met strict MRI-based diagnostic criteria for BAD, defined as a single deep subcortical infarction in the territory of a lenticulostriate or paramedian pontine artery without more than 50 percent stenosis of the corresponding parent artery. Eligibility was confirmed through centralized imaging review, and patients with transient ischemic attack, cardioembolic sources, significant large-artery stenosis, or plans to receive thrombolysis or endovascular therapy were excluded. Between November 2023 and November 2025, 516 patients were randomly assigned in a 1:1 ratio to receive either intravenous tirofiban or guideline-based antiplatelet therapy. The tirofiban regimen consisted of a loading infusion of 0.4 micrograms per kilogram per minute for 30 minutes, followed by a maintenance infusion of 0.1 micrograms per kilogram per minute for 48 hours. The control group received either aspirin alone or aspirin plus clopidogrel for 48 hours, at the treating physician’s discretion. Although the trial was open-label, the statisticians, members of the independent clinical events committee, and outcome assessors were blinded to treatment allocation, protecting the integrity of the endpoint measurements.

The primary endpoint was an excellent functional outcome at 90 days, defined as a score of 0 or 1 on the modified Rankin Scale, which ranges from 0 for no symptoms to 6 for death. The results were unequivocally negative for superiority. At 90 days, 181 of 258 patients in the tirofiban group, or 70.2 percent, achieved an excellent functional outcome, compared with 178 of 255 patients, or 69.8 percent, in the standard antiplatelet group. The unadjusted risk ratio was 1.01 with a 95 percent confidence interval of 0.90 to 1.13, and the P value of 0.93 left no statistical ambiguity: the two strategies produced essentially identical outcomes. Adjusted analyses and per-protocol analyses yielded the same conclusion, and prespecified subgroup analyses across six baseline characteristics, including age, sex, hypertension, diabetes, stroke severity, and time from onset to randomization, found no hint of treatment effect heterogeneity.

Secondary outcomes told a similarly flat story. The rate of early neurological deterioration within seven days after randomization was 8.2 percent in the tirofiban group versus 6.3 percent in the control group, a difference that was not statistically significant and, if anything, numerically favored standard therapy. Ordinal modified Rankin Scale scores at 90 days, National Institutes of Health Stroke Scale scores at 7 and 90 days, and Barthel Index scores of daily independence at 90 days all showed no meaningful advantage for tirofiban. Recurrent ischemic events were rare in both arms, with ischemic stroke occurring in 1.9 percent of tirofiban patients and 1.6 percent of control patients within 90 days, consistent with the characteristically low recurrence risk of this stroke subtype.

On the safety side, major bleeding, defined by the PLATO criteria, was strikingly rare: zero events among 259 tirofiban-exposed patients with available safety assessments versus one event among 245 control patients, and no intracranial hemorrhage occurred in the tirofiban group. Rates of serious adverse events and all-cause death were similar between groups. However, the investigators caution that such a small number of bleeding events precludes any precise comparative safety conclusion, and the findings should not be interpreted as establishing equivalent safety between the two strategies.

The negative result takes on added significance when placed alongside the broader landscape of tirofiban research. The RESCUE BT2 trial, which enrolled patients with ischemic stroke without medium or large vessel occlusion, found that early tirofiban improved the proportion achieving excellent functional outcomes, but that cohort had a higher median baseline stroke severity and a mixture of etiologies, leaving the benefit for BAD specifically unclear. The TREND trial found tirofiban reduced early neurological deterioration in non-cardioembolic strokes, but 58 percent of its participants had large artery atherosclerosis or unknown etiology. Meanwhile, the STRATEGY trial, which also targeted BAD-related stroke, similarly found that tirofiban failed to reduce deterioration. One notable feature of BRANT is that 85.5 percent of control patients received dual antiplatelet therapy during the randomized period, a level of background platelet inhibition that may itself have attenuated any incremental benefit of adding tirofiban, since the control group may already have achieved substantial antithrombotic effect.

The trial’s authors are careful to frame what the result does and does not mean. Most patients were randomized relatively late after stroke onset, with a median time from onset to randomization of about 30 hours, and more than half of all early neurological deterioration events had already occurred before randomization, limiting any opportunity for tirofiban to intervene. Concomitant oral antiplatelet therapy was also prohibited during the tirofiban infusion, a design feature that distinguishes this regimen from other tirofiban-based strategies. The findings therefore do not constitute evidence against all tirofiban-based treatment approaches, nor do they establish equivalence between the two strategies. What they do establish, with the rigor of a well-powered randomized design, is that routine empirical use of intravenous tirofiban monotherapy cannot be recommended over standard oral antiplatelets for BAD-related stroke presenting within 48 hours of onset. Future trials, the investigators suggest, should explore whether ultra-early intervention, treatment of patients with active deterioration, or alternative pathophysiological targets might finally deliver the clinical benefit that has so far eluded this stubborn and disabling stroke subtype.

Subject of Research: A phase III randomized trial of intravenous tirofiban versus standard antiplatelet therapy for acute branch atheromatous disease-related ischemic stroke

Article Title: Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial

Article References: Li, S., Hu, H., Zhang, D., Liu, B., Zhong, M., Wang, L., Yang, Q., Zhang, P., Zhao, W., Zhao, F., Tang, Y., Wang, X., Li, H., Chen, L., Chen, G., Wang, R., Dong, A., Zheng, Z., Wang, X., … Zhang, L. (2026). Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial. The Lancet Regional Health – Western Pacific, 75, Article 101995. https://doi.org/10.1016/j.lanwpc.2026.101995

Image Credits: AI Generated

DOI: 10.1016/j.lanwpc.2026.101995

Keywords: tirofiban, branch atheromatous disease, ischemic stroke, antiplatelet therapy, early neurological deterioration, randomized controlled trial, glycoprotein IIb/IIIa inhibitor, perforating arteries, modified Rankin Scale, stroke outcomes, dual antiplatelet therapy, BRANT trial

The study enrolled 334 patients who had suffered what the researchers classify as high-risk non-disabling ischemic cerebrovascular events, abbreviated HR-NICE. This category covers transient ischemic attacks and minor strokes that do not leave patients disabled but carry a high probability of recurrence. The danger window is brutally short: the risk of another vascular event is highest within the first days and weeks after the initial episode, which is precisely when early neurological deterioration tends to strike. Patients were enrolled within 24 hours of symptom onset — a demanding logistical requirement that reflects how rapidly the therapeutic window closes. Once enrolled, they were randomly assigned in a one-to-one ratio to one of two dual antiplatelet regimens: low-dose ticagrelor at 60 milligrams twice daily plus aspirin, or clopidogrel plus aspirin.

The logic behind the comparison rests on a well-known weakness of clopidogrel. The drug is a prodrug, meaning it must be converted by liver enzymes into its active form before it can inhibit platelets. The critical enzyme, CYP2C19, is encoded by a gene that varies widely between individuals. People carrying so-called loss-of-function alleles — a variant that is especially common in East Asian populations, affecting a majority of Chinese patients — convert clopidogrel poorly or not at all. For these patients, standard clopidogrel-based therapy offers substantially weaker platelet inhibition, and previous studies have linked poor clopidogrel response to early neurological deterioration after acute ischemic stroke. Ticagrelor, by contrast, is a reversible P2Y12 receptor antagonist that does not require metabolic activation, so its antiplatelet effect is essentially independent of CYP2C19 genotype.

This pharmacological distinction has already reshaped stroke care in China. The CHANCE-2 trial, published in the New England Journal of Medicine in 2021, showed that in patients carrying CYP2C19 loss-of-function alleles, ticagrelor plus aspirin outperformed clopidogrel plus aspirin in preventing recurrent stroke within 90 days. But CHANCE-2 required rapid genotyping to identify carriers — a capability that many hospitals, particularly in resource-limited settings, simply do not have. The new trial was designed with this gap in mind. Rather than genotyping patients and treating only those with the resistant variant, the investigators asked a more pragmatic question: does low-dose ticagrelor beat clopidogrel in an unselected HR-NICE population, where a large proportion of patients would be expected to carry loss-of-function alleles?

The answer was a clear yes. Early neurological deterioration within seven days — defined as an increase of at least two points on the National Institutes of Health Stroke Scale, or a one-point increase in the motor subscore compared with baseline — occurred in 10.8 percent of patients receiving ticagrelor plus aspirin, compared with 22.2 percent of those receiving clopidogrel plus aspirin. That corresponds to a relative risk of 0.55, with a 95 percent confidence interval of 0.33 to 0.92 and a p-value of 0.023. In plain terms, the ticagrelor regimen roughly halved the odds that a patient’s neurological condition would worsen in the critical first week. The trial used an intention-to-treat analysis, the most conservative approach, and its open-label design with blinded endpoint adjudication means that while treating physicians knew which drugs patients received, the researchers assessing outcomes did not — a design that minimizes bias in the primary result.

The benefits extended well beyond the first week. At 90-day follow-up, 92.8 percent of patients in the ticagrelor group had achieved an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin Scale, the standard measure of post-stroke disability. In the clopidogrel group, the figure was 80.8 percent — a statistically significant difference, with a relative risk of 1.13 and a p-value of 0.002. The rate of major ischemic vascular events within 90 days also trended in favor of ticagrelor, at 6.6 percent versus 10.8 percent, though this difference did not reach statistical significance (relative risk 0.54; p = 0.085), likely reflecting the relatively small number of events in a trial of this size.

Just as important as the efficacy signal was the safety profile, because the perennial concern with intensified antiplatelet therapy is bleeding. Dual antiplatelet regimens walk a narrow line: they must suppress platelet aggregation enough to prevent clot propagation and recurrence, but not so much that spontaneous hemorrhage becomes a hazard. In this trial, any bleeding events occurred in 6.0 percent of the ticagrelor group versus 4.2 percent of the clopidogrel group — a difference that was neither statistically significant (p = 0.563) nor clinically alarming, particularly since all bleeding events in both groups were classified as mild. Rates of adverse events overall (12.6 percent versus 10.2 percent) and serious adverse events (0.6 percent versus 1.8 percent) were similarly balanced between the groups. The low 60-milligram twice-daily dose of ticagrelor, rather than the 90-milligram dose used in cardiac patients, appears to be the key to achieving potent platelet inhibition while keeping bleeding in check.

The trial’s design details reinforce the credibility of these findings. It was registered prospectively with the Chinese Clinical Trial Registry in February 2023, conducted across multiple centers, and approved by the ethics committee of the First Affiliated Hospital of Dalian Medical University, with all patients or their legal representatives providing written informed consent. The investigators adhered to the Declaration of Helsinki and Good Clinical Practice guidelines. The primary endpoint — early neurological deterioration — is a mechanistically meaningful outcome, because it captures the dynamic process of thrombus growth and new clot formation in the vulnerable cerebral circulation, rather than merely counting later recurrent strokes. By targeting this early window, the regimen intervenes at the moment when platelet-rich thrombi are most actively propagating.

Why does the result matter globally, and not only in China? The CYP2C19 loss-of-function variant is most prevalent in East Asian populations, but it is common elsewhere too, and clopidogrel resistance is a recognized problem wherever the drug is used. Moreover, the trial’s most practical implication is precisely that it does not require genotyping. The authors conclude that the regimen may provide a safe and effective alternative antiplatelet strategy for preventing early neurological deterioration in institutions lacking rapid genotyping facilities — a description that fits the majority of stroke centers worldwide. A physician confronting a patient with a high-risk minor stroke or TIA can start low-dose ticagrelor plus aspirin immediately, without waiting for genetic test results that may take days or simply be unavailable.

Cautions remain, as they always do with a single trial. The study was conducted in China, the sample size of 334 patients is modest, and the open-label design, while mitigated by blinded endpoint assessment, cannot eliminate all performance bias. The trend toward fewer ischemic vascular events at 90 days did not reach statistical significance, and longer-term outcomes beyond three months were not assessed. Broader international replication, ideally in populations with different baseline risks and genetic backgrounds, would strengthen the evidence base. Still, the magnitude of the effect on early deterioration — the single most feared event in the days after a minor stroke — combined with a clean bleeding profile, makes this one of the more consequential antiplatelet findings in recent stroke research. For patients in the fragile hours after a warning stroke, a cheap, widely available, genotype-independent drug combination that halves the risk of getting worse is exactly the kind of pragmatic advance that changes clinical practice.

Subject of Research: Low-dose ticagrelor plus aspirin versus clopidogrel plus aspirin for preventing early neurological deterioration after high-risk non-disabling ischemic cerebrovascular events

Article Title: Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial

Article References: Liu, J., Cao, H., Wang, M., Jiao, Y., Zhou, R., Tang, Y., Chen, R., Liu, X., Shen, J., Li, D., Tian, W., Gong, X., Zhang, B., Liu, Y., & Ji, X. (2026). Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial. Journal of Neurology, 273(10), Article 568. https://doi.org/10.1007/s00415-026-14094-4

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14094-4

Keywords: ticagrelor, aspirin, clopidogrel, early neurological deterioration, minor stroke, transient ischemic attack, dual antiplatelet therapy, CYP2C19, randomized clinical trial, stroke prevention, P2Y12 inhibitor, functional outcome

The funding will support a one-year feasibility phase of the United States portion of a major international clinical trial designed to answer a deceptively simple question: is aspirin alone sufficient, or is a more intensive combination of blood-thinning medications the better approach for patients with SCAD? The study will be led by the Clinical Trial Center of Mount Sinai Fuster Heart Hospital and the Institute for Transformative Clinical Trials. If the feasibility phase succeeds, Mount Sinai will receive approximately $14 million over seven years from the NIH to launch the larger United States portion of the same trial, an investment that signals how seriously federal funders view the gap in evidence surrounding this disease.

The biological distinction at the heart of the trial is critical to understanding why it matters. In the typical heart attacks that dominate cardiology textbooks and clinical guidelines, the culprit is atherosclerosis — the gradual buildup of cholesterol-laden plaque inside the artery. When that plaque ruptures, platelets in the blood rush to the site and form clots that can completely block the vessel. Standard treatment after such an event relies heavily on antiplatelet medications, which make platelets less likely to stick together and form the clots that could cause a second attack. Decades of randomized trials in this patient population have established how aggressively such therapy should be applied.

SCAD, by contrast, is caused by a problem within the artery wall itself rather than by cholesterol buildup. A tear develops spontaneously in the layers of the vessel, and blood can accumulate within the wall, compressing the channel through which blood flows to the heart. Because the underlying pathology is fundamentally different, the rationale for applying the same intensive antiplatelet regimens is far less clear. Yet doctors have had no large, randomized trial conducted specifically in SCAD patients to guide them, and many of the treatments these patients receive today were developed and validated in entirely different populations. The result is a persistent uncertainty that affects treatment decisions made every day in emergency rooms and cardiac catheterization laboratories around the world.

The stakes are heightened by who SCAD affects. Roughly 80 to 95 percent of cases occur in women, most of whom are between 42 and 52 years old. Many have no traditional cardiovascular risk factors such as high cholesterol or diabetes, which means the condition often arrives without warning and can be mistaken for other causes of chest pain. Because SCAD disproportionately affects women at a relatively young age and without the traditional warning signs of heart disease, the researchers argue that identifying the optimal treatment is particularly important — the goal, as the trial’s leadership describes it, is to determine which treatment provides the best protection while exposing patients to the least unnecessary risk.

Roxana Mehran, MD, Mount Sinai Professor in Cardiovascular Clinical Research and Outcomes at the Icahn School of Medicine, is a Principal Investigator for the trial’s clinical coordinating center. Deepak L. Bhatt, MD, MPH, Director of Mount Sinai Fuster Heart Hospital and also a Principal Investigator of the clinical coordinating center, has emphasized that SCAD is a very different disease from the type of heart attack encountered most often, yet many treatments in use today were adopted from studies conducted in other patient populations. In his view, the trial offers an opportunity to generate the rigorous evidence that patients with SCAD and their physicians have long been waiting for — evidence that could finally place treatment of the condition on the same evidentiary footing as the care of more common heart attacks.

The trial itself, known as SCAD-ALIGN, has been designed to settle the antiplatelet question directly. It will compare a moderate antiplatelet strategy — aspirin alone for three months — against a more intensive strategy consisting of dual antiplatelet therapy for three months followed by nine months of single antiplatelet therapy. Researchers plan to enroll roughly 3,500 patients internationally, with approximately 500 of those in the United States across 60 sites. Participants will be evaluated for major cardiovascular outcomes, including cardiovascular death, myocardial infarction, recurrent SCAD, unplanned coronary revascularization, stroke, transient ischemic attack, and bleeding. That last outcome is especially important, because more aggressive blood thinning always carries an increased risk of hemorrhage, and the trial is structured to capture whether the intensive strategy’s potential benefits outweigh that hazard.

The scale of the effort reflects a fundamental challenge in studying rare diseases. SCAD is relatively uncommon, which means no single center or country can easily enroll enough patients to answer the question reliably. Alan Moskowitz, MD, Professor of Population Health Science and Policy at the Icahn School of Medicine and a Principal Investigator for the trial’s data coordinating center, has noted that the project brings together research networks and national funding organizations across multiple countries under one common study protocol. Annetine Gelijns, PhD, Chair of the Department of Population Health Science and Policy and a Principal Investigator for the data coordinating center, has added that the trial is expected to represent a novel model of international academic collaboration and to provide the first large-scale randomized evidence to help guide antiplatelet therapy in this patient population.

The collaborative architecture extends well beyond the United States. SCAD-ALIGN was endorsed by the Multinational Clinical Trials Initiative of the Global Cardiovascular Research Funders Forum, and the global collaboration includes investigators and funding organizations from the United States, Germany, the United Kingdom, Canada, the Netherlands, Denmark, Sweden, Spain, Australia, New Zealand, and other participating countries, with additional participation from centers in South America. Emilia Bagiella, PhD, Director of the Center for Biostatistics in the Department of Population Health Science and Policy and a Principal Investigator for the data coordinating center, has described this coordinated approach as intended to generate robust evidence for an important clinical question that affects women disproportionately and for which large-scale industry-sponsored research has been limited — a candid acknowledgment that commercial incentives have historically underserved conditions like SCAD.

For the patients and physicians who have navigated SCAD without the benefit of dedicated trial evidence, the launch of this feasibility phase marks a turning point. The condition’s rarity, its predilection for young and otherwise healthy women, and its fundamentally distinct mechanism have long combined to leave clinicians extrapolating from data that were never meant to apply to these patients. If the feasibility phase demonstrates that the international network can recruit and follow participants at the required scale, the full trial will proceed with the backing of approximately $14 million in NIH support over seven years, and the results could ultimately reshape treatment recommendations for SCAD patients worldwide — replacing inherited convention with evidence earned from the very population the disease affects most.

Subject of Research: An international randomized clinical trial comparing antiplatelet treatment strategies for spontaneous coronary artery dissection, a heart attack cause that predominantly affects young women.

Article Title: Mount Sinai awarded $2 million to launch international clinical trial on spontaneous coronary artery dissection

Article References: Mount Sinai awarded $2 million to launch international clinical trial on spontaneous coronary artery dissection. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: SCAD, spontaneous coronary artery dissection, Mount Sinai, NIH, clinical trial, antiplatelet therapy, aspirin, women's heart health, cardiology, SCAD-ALIGN, heart attack, dual antiplatelet therapy

The new guideline represents a substantial methodological step forward. Where the 2016 document relied on more traditional evidence appraisal, the update applies stringent Grading of Recommendations Assessment, Development, and Evaluation criteria, the current international standard for evaluating the certainty of medical evidence. The authors also performed formal meta-analyses, pooling data across studies to generate more precise estimates of benefit and harm. Five specific questions, framed in the PICO format of population, intervention, comparison, and outcome, structured the effort: whether andexanet alfa outperforms prothrombin complex concentrates for reversing direct factor Xa inhibitors; whether desmopressin helps patients on antiplatelet drugs; whether platelet transfusion improves outcomes; whether coagulopathy reversal benefits patients with very small hemorrhages; and whether viscoelastic hemostatic testing, such as thromboelastography and rotational thromboelastometry, meaningfully improves mortality, functional recovery, thrombosis rates, hemorrhage expansion, or treatment-related adverse events. Recommendations were further stratified by whether the bleeding was spontaneous or traumatic, an important distinction that reflects growing recognition that these two patient populations behave differently.

Notably, the update deliberately left many of the 2016 recommendations untouched. Reversal strategies for vitamin K antagonists such as warfarin, direct thrombin inhibitors, unfractionated heparin, low molecular weight heparin, pentasaccharides, and thrombolytics were not re-reviewed, largely because no compelling new literature had emerged that would substantively alter the prior guidance. That decision itself carries information: a decade of research has reshaped thinking in some corners of antithrombotic reversal while leaving others remarkably stable. The most dramatic shifts concern the factor Xa inhibitor antagonists, the class of oral anticoagulants that includes apixaban and rivaroxaban and that has steadily displaced warfarin in clinical practice.

The spotlight falls squarely on andexanet alfa, a recombinant decoy protein engineered to bind factor Xa inhibitors in the bloodstream and neutralize their anticoagulant effect. Early enthusiasm was fueled by the ANNEXA-4 study, which demonstrated that andexanet effectively reduced expansion of intraparenchymal hematomas. Yet adoption was hampered from the outset by the drug’s extraordinarily high cost, and Frontera’s own prior work quantified just how stark the price gap is compared with prothrombin complex concentrates, the four-factor blood products that have long served as the workhorse reversal agent. The pivotal test arrived with ANNEXA-I, a randomized trial that pitted andexanet against usual care, with 86 percent of the comparator group receiving prothrombin complex concentrates. Andexanet achieved significantly better hemostatic efficacy, but that win came with a sobering price: a 5 percent absolute increase in thrombotic events within 30 days, driven particularly by ischemic strokes. Mortality and functional outcomes showed no difference between the arms, leaving clinicians facing an uncomfortable question about which harm matters more, ongoing hematoma expansion or a treatment-emergent ischemic stroke.

The new guideline’s meta-analyses sharpened that trade-off into hard numbers. Pooling the available data suggested a modest but statistically significant 9 percent relative improvement in hemostatic efficacy for andexanet over prothrombin complex concentrates. Against that benefit stood a significant 35 percent relative increase in thrombotic events. Further meta-analyses found no mortality or functional outcome advantage for andexanet, and, perhaps most strikingly for health systems, both hospital and intensive care unit lengths of stay were longer when andexanet was used. The pharmacology helps explain the thrombosis signal: andexanet does not simply remove apixaban or rivaroxaban from the body, it floods the circulation with inert decoys that also bind endogenous tissue factor pathway inhibitor, transiently unleashing coagulation beyond the point of simple reversal. Weighing all of this, the Neurocritical Care Society recommendation now diverges sharply from its European counterpart, the European Stroke Organisation and the European Association of Neurosurgical Societies, whose expert consensus still suggests considering andexanet in adults with spontaneous intracranial hemorrhage on factor Xa inhibitors who present within 15 hours of their last dose, or with proven anti-factor Xa activity above 100 nanograms per milliliter, and within 12 hours of symptom onset. Frontera notes that the European position rests primarily on the ANNEXA-I trial alone, whereas the North American guideline synthesized multiple meta-analyses. The situation is further complicated by market reality: andexanet is no longer available in the United States as of December 2025, though it remains accessible elsewhere in the world, meaning that international practitioners must still navigate these conflicting recommendations at the bedside.

A second provocative question addressed by the guideline is whether anticoagulation reversal should be abandoned for very small hemorrhages, defined here as an intraparenchymal hematoma volume of 10 milliliters or less. The intuition seems reasonable: if a bleed is tiny, perhaps the risks of procoagulant reversal, including thrombosis, outweigh any benefit. But the trial data undercut that logic in an unexpected way. The median hematoma volume in ANNEXA-I was only 10 milliliters, and just 13 milliliters in the earlier INCH trial of vitamin K antagonist reversal. Both studies demonstrated improvements in laboratory measures of coagulopathy and reductions in hematoma expansion, suggesting that even small hemorrhages benefit from reversal. Paradoxically, the data gap lies at the other end of the spectrum: patients with very large hemorrhages were typically excluded from randomized trials, so clinicians managing the sickest patients have the least rigorous evidence to guide them.

The biology of hemorrhage location adds another layer of nuance. The same volume of blood wreaks very different degrees of damage depending on where it accumulates in the brain. A recent analysis cited in the commentary identified volume thresholds that predict poor 90-day outcomes, defined as modified Rankin scores of 4 through 6, and found that the critical threshold is substantially lower for deep hemorrhages, at 17 milliliters or more, than for lobar hemorrhages, at 36 milliliters or more. A deep bleed near critical structures such as the brainstem can be catastrophic at volumes that would be survivable in a lobar location. In other words, even modest expansion of a small deep hemorrhage could translate into substantially worse functional outcomes, which strengthens the argument that initial volume alone should not determine whether reversal is offered. Timing matters too: the time from last known well and the time since the last antithrombotic dose are key predictors of expansion, as are imaging biomarkers such as the spot sign on contrast-enhanced CT, which identifies active extravasation.

The temporal dynamics of risk provide perhaps the most persuasive clinical argument in the commentary. Within the first 48 hours after an intracerebral hemorrhage begins, the risk of hematoma expansion dwarfs the thromboembolic risk of temporarily stopping antithrombotic therapy. The danger of ischemic events off anticoagulation rises only in a delayed fashion, after several days. Even patients at extremely high thromboembolic risk, including those with mechanical heart valves and left ventricular assist devices, appear to tolerate anticoagulation reversal well, with low thromboembolic rates during the first 7 to 14 days after hemorrhage onset. Given that these are the very patients for whom clinicians most fear withholding anticoagulation, the evidence suggests the acute reversal decision can be made with relative confidence. Although the guideline authors judged the data insufficient to issue a formal recommendation on reversal for small-volume hemorrhages, Frontera argues that offering reversal in the acute window, when expansion risk peaks, is prudent regardless of initial volume or the original indication for anticoagulation.

The final significant shift concerns desmopressin, commonly known as DDAVP, a vasopressin analog that increases circulating levels of von Willebrand factor and factor VIII and has been proposed as a hemostatic agent for patients bleeding while on antiplatelet drugs such as aspirin and clopidogrel. The 2016 guideline had conditionally recommended DDAVP on the basis of low-quality evidence. Applying rigorous GRADE criteria to the accumulated data, the new meta-analyses found no significant benefit for hematoma expansion, mortality, functional outcome, or length of stay, and the guideline therefore makes no recommendation either for or against the drug. Importantly, serious adverse events were similar with and without desmopressin, both in the pooled analyses and in the DASH trial, a randomized, placebo-controlled feasibility study from the United Kingdom that established the safety foundation for a definitive phase III investigation. Both the North American and European guidelines urge enrollment of eligible patients in trials testing desmopressin’s utility, though no such phase III study is currently open. In the interim, Frontera observes that the trend toward less expansion, the demonstrated safety record, the low cost, the mechanistic plausibility, and the absence of alternative hemostatic options for antiplatelet-associated bleeding may reasonably lead practitioners to prescribe it anyway, a rare instance of a guideline update explicitly acknowledging the gap between evidence and bedside reality. The broader message is clear: for traumatic brain injury-related hemorrhage and for hemostatic agents in antiplatelet bleeding, the field still needs well-designed trials before certainty can replace consensus.

Subject of Research: Emergency reversal of antithrombotic therapy in adult intracranial hemorrhage per a 2026 neurocritical care guideline update

Article Title: Commentary on: Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and Society of Critical Care Medicine

Article References: Frontera, J. A. (2026). Commentary on: Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocritical Care. https://doi.org/10.1007/s12028-026-02639-4

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02639-4

Keywords: intracranial hemorrhage, anticoagulation reversal, andexanet alfa, prothrombin complex concentrate, desmopressin, factor Xa inhibitors, hematoma expansion, Neurocritical Care Society, GRADE methodology, antiplatelet therapy, thromboembolism, viscoelastic testing

The research, published in the open-access journal Nursing Open, took an unusual analytical approach: instead of studying patients as single units, the investigators examined every recorded haemodialysis session over a full year, from January to December 2021, in patients treated through tunnelled catheters within a national renal foundation network in Spain. The result was a dataset of 40,193 sessions from 743 patients, of which 987 sessions, or 2.5 percent, met the study’s operational definition of intradialytic catheter dysfunction. That definition was grounded in internationally recognised KDOQI thresholds: a machine-registered dysfunction flag appeared whenever blood flow fell below 300 millilitres per minute while arterial pre-pump pressure dropped below minus 250 millimetres of mercury, venous return pressure rose above plus 250 millimetres of mercury, or both, at the start of the session or at the 60-minute mark. Nursing staff then verified each flagged event in the electronic dialysis record system.

The cohort itself was clinically striking. The patients averaged 68.4 years of age and carried a heavy burden of chronic disease: 84.5 percent had arterial hypertension, 60.1 percent had cardiovascular disease, and nearly half lived with diabetes. Diabetic nephropathy was the leading cause of kidney failure, accounting for 34.3 percent of cases. Notably, women made up 63.7 percent of the cohort, a marked contrast with national registry data in which men typically account for roughly two-thirds of the haemodialysis population, a difference the authors attribute to the particular clinical profile of patients who end up dialysing through tunnelled catheters rather than through surgically created arteriovenous fistulas.

When the researchers compared dysfunctional sessions with smooth-running ones, the haemodynamic signatures diverged sharply, exactly as the outcome definition would predict. Sessions with dysfunction began with a mean blood flow of 257.9 millilitres per minute versus 350.7 in healthy sessions, and by the 60-minute mark the gap persisted, with flows of 256 versus 358.3. Arterial pressures plunged dramatically deeper into negative territory, averaging minus 215.2 millimetres of mercury across dysfunctional sessions compared with minus 172.2 in uneventful ones. Total blood volume processed fell from 75.6 litres to 56.2, and the final Kt, the routinely recorded marker of the dialysis dose actually delivered, dropped from 48.2 litres to 39.1. In plain terms, a failing catheter deprived patients of nearly a fifth of the intended cleansing capacity of each session.

Beyond the intradialytic pressure readings themselves, which the authors are careful to frame as manifestations of dysfunction rather than causes of it, the analysis identified baseline characteristics that clustered with failing sessions. Catheters placed in the left internal jugular vein showed a dysfunction rate of 5.1 percent, dramatically higher than the 0.7 percent observed with the right internal jugular vein, the most popular insertion site in the cohort. Femoral placement, though rare, performed poorly, with the right femoral vein showing dysfunction in 6.3 percent of sessions, consistent with earlier evidence that femoral and subclavian sites carry higher thrombotic and mechanical risks. Comorbidities also left fingerprints: diabetes, cardiopathy, peripheral arterial disease, prior stroke, and a history of malignancy were all significantly more frequent in dysfunctional sessions, as was systemic anticoagulant therapy, though the authors caution this may reflect the vascular risk profile of the patients rather than a drug effect.

Perhaps the most technically revealing part of the study was its stratification of dysfunction events into arterial and venous types. Of the 1,481 recorded events, 1,346 were arterial and 135 were venous, and the two behaved like distinct clinical entities. Arterial events featured severely negative pre-pump pressures, averaging minus 221.9 millimetres of mercury, signalling that the catheter was struggling to draw blood in, and were more common in older patients with hypertension, cerebrovascular disease, and prior SARS-CoV-2 infection. Venous events, by contrast, showed soaring return pressures averaging 220.4 millimetres of mercury, indicating obstruction on the outflow side, and occurred disproportionately in men, in patients with peripheral arterial disease, tumours, previous kidney transplants, and those on anticoagulants. Venous events also produced significantly lower final Kt values, suggesting the outflow type of failure may be particularly punishing for dialysis adequacy.

Two management variables, line reversal and 5 percent sodium heparin locking solution, appeared far more often in dysfunctional sessions, with line reversal documented in 3.5 percent of sessions without dysfunction versus an elevated share within dysfunctional ones, and 5 percent heparin locks showing a 4.3 percent dysfunction rate against 2 percent for the standard 1 percent heparin. But the researchers explicitly warn against reading these numbers causally. In routine practice, clinicians reverse catheter lines and escalate locking solutions precisely because a catheter is already underperforming, so the association plausibly reflects a rescue response rather than a culprit. This principle of reverse causality and confounding by indication permeates the entire analysis and is one of the paper’s most intellectually honest contributions to a field where such distinctions are often blurred.

The pharmacological findings followed the same cautious logic. Overall, systemic antiplatelet therapy showed no significant association with dysfunction when analysed as a single binary variable, yet drug-specific comparisons revealed significant heterogeneity, with acetylsalicylic acid regimens, clopidogrel, prasugrel, and dipyridamole each showing different dysfunction frequencies. Among anticoagulants, enoxaparin and especially tinzaparin were the agents most frequently associated with dysfunction events, while combined regimens such as enoxaparin with warfarin appeared far less often in failing sessions. The authors interpret these patterns as exploratory and hypothesis-generating, likely shaped by differences in patient indication and underlying vascular disease rather than by direct pharmacological effects on catheter patency, and they point to prior trials of agents like recombinant tissue plasminogen activator and taurolidine-based locks as avenues where randomised evidence has begun to clarify what observational data cannot.

Dialysis efficacy emerged as a second major storyline. Using sex-specific operational Kt thresholds, the researchers classified 24.7 percent of sessions as low efficacy, 20.8 percent as normal, and 52.6 percent as optimal. The sex split was dramatic: 41.4 percent of male patients’ sessions fell into the low-Kt category, while 65.6 percent of women’s sessions reached the optimal range, a highly significant difference partly attributable to the fact that Kt depends on body size, and men on average process more blood volume through larger bodies. Because Kt was measured session-by-session through ionic dialysance rather than sampled sporadically, the study demonstrates how continuous, per-session adequacy monitoring can flag patients at risk of chronic under-dialysis, particularly catheter-dependent men, long before cumulative toxin buildup becomes clinically apparent.

The study’s limitations are considerable and openly acknowledged. The analysis was univariate and did not adjust for the fact that dozens of sessions belonged to the same patient, which may have inflated statistical significance. Being retrospective and built on routine electronic records, it could not capture insertion technique, operator experience, catheter tip design or position, or fibrin sheath formation, all recognised determinants of catheter survival, and all data came from a single institutional network, limiting generalisability. Still, the practical message is clear and actionable: continuous vigilance over blood flows, line pressures, and pressure trajectories during every dialysis session can catch failing catheters early, and the distinct arterial-versus-venous signatures described here give nurses and nephrologists a framework for interpreting what the machine alarms are actually telling them. The authors call for adjusted analytical studies, trials of locking strategies and anticoagulation protocols, and exploration of nursing-led interventions, all aimed at turning a descriptive atlas of catheter failure into genuine prediction and prevention.

Subject of Research: Clinical and technical factors associated with tunnelled central venous catheter dysfunction in haemodialysis patients

Article Title: Clinical and Technical Factors Associated With Tunnelled Central Venous Catheter Dysfunction in Haemodialysis: A Multicentre Session‐Level Retrospective Study

Article References: Gimeno Hernán, V., Perez Ingidua, C., Rivas Paterna, A. B., Moreno, G., Vicente‐Galán, M. J., Orgaz‐Rivas, E., Meneses‐Monroy, A., & Ortuño‐Soriano, I. (2026). Clinical and Technical Factors Associated With Tunnelled Central Venous Catheter Dysfunction in Haemodialysis: A Multicentre Session‐Level Retrospective Study. Nursing Open, 13(9), Article e70758. https://doi.org/10.1002/nop2.70758

Image Credits: AI Generated

DOI: 10.1002/nop2.70758

Keywords: haemodialysis, central venous catheter, catheter dysfunction, dialysis adequacy, Kt, vascular access, anticoagulation, antiplatelet therapy, nephrology, internal jugular vein, retrospective study, nursing

The review, led by Ali Msheik of Hamad Medical Corporation in Doha, Qatar, together with colleagues in trauma surgery, neurocritical care, and medical ethics, synthesized all available systematic reviews of viscoelastic hemostatic assays in neurocritical illness. These assays, which include thromboelastography known as TEG, TEG Platelet Mapping, and rotational thromboelastometry known as ROTEM, differ fundamentally from standard coagulation tests. Instead of isolating plasma and timing a single clotting reaction, they measure the actual physical behavior of clot formation in whole blood: how quickly the clot initiates, how strongly it propagates, how firm the final clot becomes, and how readily fibrinolysis breaks it down. In principle, this gives clinicians a real-time picture of hemostasis that standard tests cannot capture.

To assess the accumulated evidence, the researchers followed PRISMA 2020 reporting guidelines, the Joanna Briggs Institute manual for umbrella reviews, and MOOSE recommendations, searching PubMed, Embase, Scopus, the Cochrane Library, and Web of Science from database inception to January 2026. Two physician reviewers with experience in neurocritical care independently screened records, extracted data, and appraised methodological quality. The screening funnel was dramatic: of 272 records identified, 199 were screened after duplicate removal, and only four systematic reviews survived full-text assessment. The authors emphasized that this narrowing reflects the strict restriction to review-level evidence with reproducible methods and extractable neuro-specific data, not a post hoc reshaping of the question.

Those four reviews encompassed 73 study occurrences representing 63 unique primary studies, spanning traumatic brain injury, subarachnoid hemorrhage, and mixed populations with ischemic stroke and coronary artery disease. A corrected covered area analysis quantified how much the underlying evidence overlapped, finding only slight overall redundancy at 5.3 percent. Within traumatic brain injury, however, the two dedicated reviews shared 12 primary studies, a corrected covered area of 29.4 percent, while the subarachnoid hemorrhage and antiplatelet therapy reviews shared no studies with other clusters. This low overall overlap means the field is not merely recycling the same small trials, an encouraging sign for the maturity of the evidence base even as quality concerns remain.

The methodological appraisal revealed uneven rigor. Using AMSTAR-2, a validated tool for assessing systematic reviews, only one review, a 2021 meta-analysis of thromboelastography in traumatic brain injury by Cannon and colleagues, achieved moderate confidence, supported by a registered protocol, a comprehensive search, duplicate screening, and structured bias assessment. The remaining reviews earned low or critically low confidence ratings owing to absent protocols, incomplete reporting of excluded studies, and limited transparency. When the authors then applied GRADE criteria to rate certainty in individual outcomes, most estimates in traumatic brain injury and subarachnoid hemorrhage fell to low or very low certainty, a consequence of predominantly observational designs, inconsistent definitions, and imprecise effects.

Within those constraints, the prognostic signal was remarkably consistent. Across two reviews covering 32 unique studies in traumatic brain injury, viscoelastic assays repeatedly identified clinically relevant coagulation disturbances. Abnormal clot strength and disturbed fibrinolytic activity were associated with mortality across 18 observational studies, with radiographic hemorrhage progression in 14 studies, and with the need for neurosurgical intervention in nine, though confounding and heterogeneous outcome definitions limited those latter findings. In subarachnoid hemorrhage, a single review of 19 primary studies found that hypercoagulable profiles, particularly increased clot firmness, were consistently linked to delayed cerebral ischemia in six studies and to early brain injury severity in four. These associations make biological sense: dysregulated clot formation and breakdown plausibly contribute to secondary brain injury, hemorrhage expansion, and delayed ischemia after aneurysm rupture.

The therapeutic story was different. No review provided convincing evidence that viscoelastic-guided interventions improved outcomes in traumatic brain injury or subarachnoid hemorrhage, meaning the assays currently function as crystal balls rather than steering wheels in these conditions. The one bright spot came from mixed ischemic populations: moderate-certainty evidence from a meta-analysis of ten studies, including randomized trials, suggested that TEG-guided antiplatelet therapy in patients with ischemic stroke and coronary artery disease was associated with fewer composite ischemic and bleeding events than standard care. Mortality effects, however, remained uncertain because reporting was sparse and inconsistent, and because the population blended cardiac and cerebrovascular patients, the finding cannot be directly transferred to pure stroke care without further validation.

The authors are explicit about what this means for practice. Viscoelastic assays, they conclude, may be most appropriately used as adjunctive diagnostic and prognostic tools in neurocritical care rather than as standalone guides for transfusion or hemostatic treatment decisions in brain trauma and aneurysmal hemorrhage. The finding challenges a seductive assumption, one that has driven adoption in trauma and cardiac surgery, that simply identifying a coagulation disturbance and acting on it automatically improves outcomes. In the neurocritical setting, the leap from detection to benefit has not yet been demonstrated in rigorous trials, and current clinical guidelines accordingly do not recommend routine viscoelastic testing in these populations.

Several structural obstacles help explain the gap between prognostic promise and therapeutic proof. Included studies frequently came from single centers using institution-specific protocols, with inconsistent assay platforms, variable clinical cutoffs, and differing transfusion and antiplatelet practices. Without harmonized thresholds and standardized definitions of what counts as an actionable abnormality, clinicians cannot translate an abnormal tracing into a uniform treatment decision, and trialists cannot pool results meaningfully. These limitations reduce generalizability and complicate the interpretation of every association reported to date.

The research agenda that follows is clear. The authors call for large prospective neuro-specific cohorts using standardized viscoelastic thresholds, randomized trials testing VHA-guided transfusion or reversal strategies specifically in traumatic brain injury and subarachnoid hemorrhage, harmonization of assay parameters and clinical definitions, mechanistic studies linking viscoelastic abnormalities to neurovascular pathophysiology, and targeted evaluation of TEG-guided antiplatelet therapy in stroke populations alone. Until that work is done, the review suggests, clinicians and policymakers should read abnormal viscoelastic findings as important prognostic information, valuable for risk stratification and communication, while resisting the temptation to build treatment algorithms on evidence that has yet to bear their weight. For a technology that has already transformed hemostasis management in trauma and cardiac surgery, neurocritical care remains the unfinished frontier.

Subject of Research: Viscoelastic hemostatic assays for prognosis and treatment guidance in neurocritical illness

Article Title: The utility of viscoelastic hemostatic assays in neurocritical illness

Article References: Msheik, A., Peralta, R., Al-Rumaihi, G., Rizoli, S., Al Mokdad, Z., de Oliveira Manoel, A. L., & Al-Thani, H. (2026). The utility of viscoelastic hemostatic assays in neurocritical illness. Journal of Emergency and Disaster Medicine, 2(1), Article 10. https://doi.org/10.1007/s44467-026-00012-1

Image Credits: AI Generated

DOI: 10.1007/s44467-026-00012-1

Keywords: viscoelastic hemostatic assays, thromboelastography, ROTEM, traumatic brain injury, subarachnoid hemorrhage, ischemic stroke, coagulopathy, neurocritical care, umbrella review, antiplatelet therapy, delayed cerebral ischemia, GRADE evidence